Skip to main content
PMC home page
The BMJ logoLink to The BMJ
editorial
. 1992 Jun 27;304(6843):1644–1646. doi: 10.1136/bmj.304.6843.1644

Selective serotonin reuptake inhibitors.

J G Edwards
PMCID: PMC1882380  PMID: 1633513

Full text

PDF
1644

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D., Fineberg N., Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol. 1991 Spring;6(1):51–58. doi: 10.1097/00004850-199100610-00007. [DOI] [PubMed] [Google Scholar]
  2. Burton S. W. A review of fluvoxamine and its uses in depression. Int Clin Psychopharmacol. 1991 Dec;6 (Suppl 3):1–21. doi: 10.1097/00004850-199112003-00001. [DOI] [PubMed] [Google Scholar]
  3. Chouinard G., Goodman W., Greist J., Jenike M., Rasmussen S., White K., Hackett E., Gaffney M., Bick P. A. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26(3):279–284. [PubMed] [Google Scholar]
  4. Cooper G. L. The safety of fluoxetine--an update. Br J Psychiatry Suppl. 1988 Sep;(3):77–86. [PubMed] [Google Scholar]
  5. Cottraux J., Mollard E., Bouvard M., Marks I., Sluys M., Nury A. M., Douge R., Cialdella P. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1990 Jan;5(1):17–30. doi: 10.1097/00004850-199001000-00002. [DOI] [PubMed] [Google Scholar]
  6. Dechant K. L., Clissold S. P. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991 Feb;41(2):225–253. doi: 10.2165/00003495-199141020-00007. [DOI] [PubMed] [Google Scholar]
  7. Doogan D. P., Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992 Feb;160:217–222. doi: 10.1192/bjp.160.2.217. [DOI] [PubMed] [Google Scholar]
  8. Doogan D. P. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol. 1991 Dec;6 (Suppl 2):47–56. doi: 10.1097/00004850-199112002-00007. [DOI] [PubMed] [Google Scholar]
  9. Dunbar G. C., Cohn J. B., Fabre L. F., Feighner J. P., Fieve R. R., Mendels J., Shrivastava R. K. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry. 1991 Sep;159:394–398. doi: 10.1192/bjp.159.3.394. [DOI] [PubMed] [Google Scholar]
  10. Edwards J. G., Goldie A., Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology (Berl) 1989;97(1):96–98. doi: 10.1007/BF00443420. [DOI] [PubMed] [Google Scholar]
  11. Guy S., Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. J Clin Psychiatry. 1990 Dec;51 (Suppl B):37–39. [PubMed] [Google Scholar]
  12. Hall J. Fluoxetine: efficacy against placebo and by dose--an overview. Br J Psychiatry Suppl. 1988 Sep;(3):59–63. [PubMed] [Google Scholar]
  13. Halman M., Goldbloom D. S. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry. 1990 Sep 15;28(6):518–521. doi: 10.1016/0006-3223(90)90485-k. [DOI] [PubMed] [Google Scholar]
  14. Henry J. A. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol. 1991 Dec;6 (Suppl 3):41–47. doi: 10.1097/00004850-199112003-00004. [DOI] [PubMed] [Google Scholar]
  15. Meltzer H. Y., Young M., Metz J., Fang V. S., Schyve P. M., Arora R. C. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979;45(2):165–175. doi: 10.1007/BF01250091. [DOI] [PubMed] [Google Scholar]
  16. Miller L. G., Bowman R. C., Mann D., Tripathy A. A case of fluoxetine-induced serum sickness. Am J Psychiatry. 1989 Dec;146(12):1616–1617. doi: 10.1176/ajp.146.12.1616. [DOI] [PubMed] [Google Scholar]
  17. Montgomery S. A., Dufour H., Brion S., Gailledreau J., Laqueille X., Ferrey G., Moron P., Parant-Lucena N., Singer L., Danion J. M. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl. 1988 Sep;(3):69–76. [PubMed] [Google Scholar]
  18. Muijen M., Roy D., Silverstone T., Mehmet A., Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand. 1988 Sep;78(3):384–390. doi: 10.1111/j.1600-0447.1988.tb06353.x. [DOI] [PubMed] [Google Scholar]
  19. Mullin J. M., Pandita-Gunawardena V. R., Whitehead A. M. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Pract. 1988 Feb;42(2):51–55. [PubMed] [Google Scholar]
  20. Reimherr F. W., Chouinard G., Cohn C. K., Cole J. O., Itil T. M., LaPierre Y. D., Masco H. L., Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990 Dec;51 (Suppl B):18–27. [PubMed] [Google Scholar]
  21. Szabadi E. Fluvoxamine withdrawal syndrome. Br J Psychiatry. 1992 Feb;160:283–284. doi: 10.1192/bjp.160.2.283b. [DOI] [PubMed] [Google Scholar]
  22. Teicher M. H., Glod C., Cole J. O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990 Feb;147(2):207–210. doi: 10.1176/ajp.147.2.207. [DOI] [PubMed] [Google Scholar]
  23. Upward J. W., Edwards J. G., Goldie A., Waller D. G. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol. 1988 Oct;26(4):399–402. doi: 10.1111/j.1365-2125.1988.tb03397.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wilcox J. A. Abuse of fluoxetine by a patient with anorexia nervosa. Am J Psychiatry. 1987 Aug;144(8):1100–1100. doi: 10.1176/ajp.144.8.1100b. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES